Capricor Therapeutics price target raised to $43 from $41 at Roth Capital

Roth Capital raised the firm’s price target on Capricor Therapeutics (CAPR) to $43 from $41 and keeps a Buy rating on the shares. The firm is updating its model while expecting an AdComm meeting in Q2 and Deramiocel approval by the PDUFA date of August 22, 2026 or a few days before, given the agent’s first-in-class potential and the opportunity to treat both cardiac and skeletal function improvements in DMD patients, the analyst tells investors in a research note.